SEATTLE, June 15, 2016 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing treatments for life-threatening inherited liver diseases in children, today announced that the company will be presenting at the 2016 JMP Securities Life Sciences Conference. Robert W. Overell, Ph.D., President and Chief Executive Officer, will provide an overview of the company and its development stage programs on Wednesday, June 22, 2016 at 9:30 a.m. EDT (6:30 a.m. PDT). The investor conference will be held from June 21-22, 2016 in New York.
A live audio webcast and replay will be available in the Investors section of PhaseRx's corporate website at www.phaserx.com.
PhaseRx is a leading mRNA development stage biopharmaceutical company dedicated to developing products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of twelve and are characterized by the body's inability to remove ammonia from the blood. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA TechnologyTM platform. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.
Head of Investor Relations
Robert H. Uhl
Westwicke Partners, LLC
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/phaserx-to-present-at-the-2016-jmp-securities-life-sciences-conference-300284766.html
SOURCE PhaseRx, Inc.